Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assays.

Blood advances·2026
Same author

Successful Treatment of Heavy Menstrual Bleeding in a Woman With Mild Haemophilia A Using Efanesoctocog Alfa.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

An Unusual Association Between Acquired Hemophilia A and Type 2 Autoimmune Pancreatitis.

Hamostaseologie·2026
Same author

The Swiss Haemophilia Registry-Report From the First 8 Years.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants.

Frontiers in pharmacology·2026
Same author

Hemophilia Severity and Its Association With Mental Health and Health-Related Quality of Life-Results From a Cross-Sectional Multicenter Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Related Experiment Video

Updated: Jun 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[The new antithrombotics in 2009].

Pierre Fontana1, Henri Bounameaux

  • 1Service d'angiologie et d'hémostase, Département de médecine interne HUG, 1211 Genève 14. Pierre.Fontana@hcuge.ch

Revue Medicale Suisse
|March 11, 2009
PubMed
Summary
This summary is machine-generated.

New anticoagulant and antiplatelet drugs are emerging for preventing blood clots, especially after orthopedic surgery. Oral factor Xa inhibitors and direct thrombin inhibitors, along with novel antiplatelet agents like prasugrel, show promise in clinical development.

Related Experiment Videos

Last Updated: Jun 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Clinical Drug Development

Context:

  • Current anticoagulants include unfractionated heparin, low-molecular-weight heparins, fondaparinux, and oral vitamin K antagonists.
  • Major orthopedic surgery poses a significant risk for thromboprophylaxis.
  • Aspirin is a primary antiplatelet agent, with ongoing research into combination therapies and clopidogrel dosing.

Purpose:

  • To review the current landscape and emerging agents in anticoagulant and antiplatelet therapy.
  • To highlight new oral anticoagulants (NOACs) and advanced antiplatelet drugs in clinical development.
  • To discuss their potential introduction and application in thromboprophylaxis, particularly in Switzerland.

Summary:

  • Parenteral anticoagulants and oral vitamin K antagonists are currently used.
  • Oral factor Xa inhibitor rivaroxaban and oral direct thrombin inhibitor dabigatran etexilate are nearing market introduction for thromboprophylaxis post-orthopedic surgery.
  • Prasugrel, a novel thienopyridine, is the most advanced antiplatelet agent in clinical development, with research also focusing on antiplatelet combinations and clopidogrel administration.

Impact:

  • The introduction of new oral anticoagulants and advanced antiplatelet agents is expected to change thromboprophylaxis strategies.
  • These novel drugs offer potential advantages in efficacy and administration convenience.
  • Further clinical evaluation will determine their optimal role in preventing thromboembolic events.